Knee Implant Price: In the wake of recent judicial examination of steep price mark-ups on medical devices and drugs, the National Pharmaceutical Pricing Authority (NPPA) has prolonged the price ceiling on orthopaedic knee implants used in knee replacement systems for at least an additional two months, extending it until January 2027.

Knee Implant Price Update

In a notification dated 13 November, the drug price regulator stated that the fixed price ceiling for orthopaedic knee implants will remain effective for up to two more months, until 15 January 2027, unless altered by a later notification. This announcement arrives as manufacturers and industry associations have submitted requests to lift the price ceiling. “Among the reasons they provided are fluctuations in foreign exchange rates, increases in labour and freight costs, a rise in the Wholesale Price Index (WPI), and supply chain challenges,” sources familiar with the matter told Business Standard.

The regulator also mentioned that the NPPA is reviewing the representations received from manufacturers and industry groups on this issue. Nevertheless, domestic medtech industry organisations have welcomed the extension, highlighting that it brings policy stability and prevents any premature hikes in implant prices.

NPPA Gives Major Relief

“The decision also allows sufficient time for a thorough evaluation of actual market conditions, including domestic production capacity, government procurement prices, the price to distributor (PTD) to MRP differentials, and the availability of advanced technologies within the current pricing framework,” stated Rajiv Nath, forum coordinator at the Association of Indian Medical Devices Industry (AIMED).

The NPPA initially set the ceiling price for orthopaedic knee implants in 2017 by invoking extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, for a one-year period. Since then, the time limit for this price ceiling has been extended annually, with the most recent extension announced on 10 September last year.

Earlier orders by the NPPA had observed that unjustified, unreasonable, and excessively high trade margins on orthopaedic knee implants resulted in exorbitant prices, significantly increasing out-of-pocket expenses for patients. Paragraph 19 of the DPCO garnered attention in 2026 when the Supreme Court highlighted mark-ups as high as 1,000 per cent on essential medicines and medical consumables.

A Bench comprising Justices Vikram Nath and Sandeep Mehta questioned the regulatory distinction between scheduled (price-capped) and non-scheduled (non-price-capped) medicines under the DPCO, as well as whether medicines deemed non-essential should remain outside price control regulations. As a result, the NPPA invoked Paragraph 19 to cap trade margins on 137 non-scheduled cancer drugs—covering more than 1,300 separate brands and dosage forms—at 30 per cent of their maximum retail price (MRP).